Lisata Therapeutics (LSTA) News Today $3.16 +0.33 (+11.66%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Brokers Issue Forecasts for LSTA Q1 EarningsNovember 1 at 2:39 AM | americanbankingnews.comLisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor EventsOctober 31 at 8:30 AM | globenewswire.comLisata Therapeutics entered research agreement with University of CincinnatiOctober 28, 2024 | markets.businessinsider.comLisata Therapeutics strikes research partnership to investigate new treatment for endometriosisOctober 28, 2024 | proactiveinvestors.comLisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of EndometriosisOctober 28, 2024 | globenewswire.comRAPT Therapeutics (NASDAQ:RAPT) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comLisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor EventsOctober 3, 2024 | finance.yahoo.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock Quotes, Forecast and News SummarySeptember 27, 2024 | benzinga.comStrong Buy Rating for Lisata Therapeutics Backed by Promising Certepetide Clinical PerformanceSeptember 19, 2024 | markets.businessinsider.comLisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER TrialSeptember 17, 2024 | finance.yahoo.comLisata Therapeutics begins treating second cohort of patients in bile duct cancer trialSeptember 17, 2024 | proactiveinvestors.comLisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor EventsSeptember 9, 2024 | globenewswire.comLisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of CholangiocarcinomaSeptember 5, 2024 | finance.yahoo.comLisata Therapeutics' certepetide receives Orphan Drug Designation for cholangiocarcinomaSeptember 5, 2024 | proactiveinvestors.comLisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of CholangiocarcinomaSeptember 5, 2024 | globenewswire.comWill Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely?August 22, 2024 | finance.yahoo.comLisata Therapeutics: Strong Buy Rating on Robust Financials and Promising Clinical TrialsAugust 13, 2024 | markets.businessinsider.comLisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | msn.comLSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024August 12, 2024 | investorplace.comLisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 12, 2024 | markets.businessinsider.comLisata Therapeutics coming off strong 2Q performance, CEO saysAugust 12, 2024 | proactiveinvestors.comLisata Therapeutics CMO details pancreatic cancer research collaboration with Haystack Oncology - ICYMIJuly 27, 2024 | proactiveinvestors.comLisata Therapeutics (NASDAQ:LSTA) Stock Quotes, Forecast and News SummaryJuly 22, 2024 | benzinga.comHaystack Oncology And Lisata Therapeutics Partner To Evaluate Efficacy Of Pancreatic Cancer TherapyJuly 19, 2024 | markets.businessinsider.comHaystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer TherapyJuly 19, 2024 | finance.yahoo.comEXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy EfficacyJuly 19, 2024 | msn.comLisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy researchJuly 18, 2024 | proactiveinvestors.comHaystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer TherapyJuly 18, 2024 | globenewswire.comLisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancerJuly 16, 2024 | proactiveinvestors.comLisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line CholangiocarcinomaJuly 16, 2024 | globenewswire.comLisata's certepetide showing promising early results as cholangiocarcinoma treatment – ICYMIJuly 13, 2024 | proactiveinvestors.comLisata Therapeutics shares promising pre-clinical dataJuly 10, 2024 | proactiveinvestors.comLisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical ModelJuly 10, 2024 | globenewswire.comLisata Therapeutics CEO discusses enrollment milestone for pancreatic cancer trialJune 18, 2024 | proactiveinvestors.comLisata Therapeutics completes pancreatic cancer cohort enrollment in CENDIFOX trialJune 13, 2024 | proactiveinvestors.comLisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX TrialJune 13, 2024 | globenewswire.comHow does Lisata Therapeutics have a negative enterprise value?May 29, 2024 | proactiveinvestors.comLisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor EventsMay 28, 2024 | globenewswire.comBuy Rating on Lisata Therapeutics Backed by Regulatory Milestones and Promising Study ProgressMay 21, 2024 | markets.businessinsider.comLisata Therapeutics receives waiver for pediatric studies of certepetide in pancreatic cancerMay 20, 2024 | proactiveinvestors.comLisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic CancerMay 20, 2024 | globenewswire.comPositive Outlook for Lisata Therapeutics as Analyst Reaffirms Buy Rating Amid Strong Financials and Promising Clinical TrialsMay 10, 2024 | markets.businessinsider.comQ1 2024 Lisata Therapeutics Inc Earnings CallMay 10, 2024 | finance.yahoo.comLisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comLisata Therapeutics reports strong 1Q performance, cash to support operations into 2026May 9, 2024 | proactiveinvestors.comLisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | globenewswire.comLisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor EventsMay 8, 2024 | finance.yahoo.comLisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024May 2, 2024 | globenewswire.comSell Rating on Sage Therapeutics Amid Zurzuvae Sales Concerns and Pipeline RisksApril 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE)April 25, 2024 | markets.businessinsider.com Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now. Click here to see it because it’s a SHOCKER… LSTA Media Mentions By Week LSTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LSTA News Sentiment▼0.600.38▲Average Medical News Sentiment LSTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LSTA Articles This Week▼101▲LSTA Articles Average Week Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kentucky First Federal Bancorp News Today PowerUp Acquisition News Today Oramed Pharmaceuticals News Today InflaRx News Today Oncolytics Biotech News Today Aileron Therapeutics News Today Kazia Therapeutics News Today Purple Biotech News Today BeyondSpring News Today Protalix BioTherapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LSTA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
